title: Effect of bromocriptine on cardiovascular complications associated with metabolic syndrome in fructose fed rats.
abstract: OBJECTIVE
  The objective of the present study was to evaluate the effect of bromocriptine on cardiovascular complications associated with type-2 diabetes mellitus (DM).
  
  
  METHODS
  Metabolic syndrome or type 2 DM was induced by administration of fructose (66% solution, p.o.) in rats. Bromocriptine mesylate (10 mg/kg, i.p.) was given in fructose-treated rats for a period of 6 weeks after induction of diabetes. After drug treatment, the parameters such as body weight, food and water intake, serum glucose, triglycerides, cholesterol, insulin, and blood pressure (BP) were measured weekly and at the end of study. At the end of treatment, BP was determined by invasive method and vascular reactivity was tested with adrenaline (Adr), noradrenaline (NA), and phenylephrine (PE). Acetylcholine-induced vasorelaxation was tested on isolated rat aorta and histopathology of hearts was also done.
  
  
  RESULTS
  Fructose-fed rats showed significant weight gain, hyperglycemia, hyperlipidemia, hyperinsulinemia, and rise of BP. Administration of bromocriptine at a dose 10 mg/kg, i.p. significantly decreased weight gain, serum glucose, triglyceride, cholesterol and insulin levels in rats fed on fructose. Bromocriptine also significantly reduced elevated BP in fructose-fed hypertensive rats. Chronic treatment with bromocriptine significantly improved the relaxant response to acetylcholine on fructose-fed hyperinsulinemic rat aorta and also reduced the pressor response to Adr, NA, and PE. Bromocriptine also showed a protection from hypertrophy and degenerative changes in myocardium.
  
  
  CONCLUSIONS
  Bromocriptine has beneficial effect in reduction of cardiovascular complications associated with metabolic syndrome.
authors.affiliation: Department of Pharmacology, M.V.P.S. College of Pharmacy, Gangapur Road, Nashik, Maharashtra, India.
authors.forename: Vandana S
authors.initials: VS
authors.lastname: Nade
authors.forename: Laxman A
authors.initials: LA
authors.lastname: Kawale
authors.forename: Umesh B
authors.initials: UB
authors.lastname: Todmal
authors.forename: Anjali B
authors.initials: AB
authors.lastname: Tajanpure
mesh_terms: D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects / Q000502:physiology; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure; D001971:Bromocriptine / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D004032:Diet; D018491:Dopamine Agonists / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005632:Fructose; D006339:Heart Rate; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008687:Metformin / Q000008:administration & dosage; D009206:Myocardium / Q000473:pathology; D000077205:Pioglitazone; D051381:Rats; D017208:Rats, Wistar; D045162:Thiazolidinediones / Q000008:administration & dosage; D014280:Triglycerides / Q000097:blood; D014664:Vasodilation / Q000187:drug effects
chemical_list: D001786:Blood Glucose; D018491:Dopamine Agonists; D007004:Hypoglycemic Agents; D007328:Insulin; D045162:Thiazolidinediones; D014280:Triglycerides; D005632:Fructose; D001971:Bromocriptine; D008687:Metformin; D002784:Cholesterol; D000077205:Pioglitazone